Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease

Journal of the American College of Cardiology

Volumn 64, Issue 14, 2014, Pages 1430-1436

  Hamon, Martial ^a,b   Lemesle, Gilles ^c,d   Tricot, Olivier ^e   Meurice, Thibaud ^f   Deneve, Michel ^c   Dujardin, Xavier ^g   Brufau, Jean Michel ^h   Bera, Jerome ^f   Lamblin, Nicolas ^c,d   Bauters, Christophe ^c,d  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

^e Centre Hospitalier de Dunkerque   (France)

^f Polyclinique du bois   (France)

^g Centre Hospitalier de Boulogne sur mer   (France)

^h Polyclinique Vauban   (France)

Author keywords

antiplatelet agent; coronary artery disease; major bleeding; oral anticoagulant; outcome; vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VITAMIN K GROUP;

ACUTE HEART FAILURE; AGED; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; BLEEDING; BODY MASS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING CORONARY STENT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEMOPERICARDIUM; HUMAN; HYPERTENSION; INCIDENCE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PROGNOSIS; PROSPECTIVE STUDY; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; SECONDARY PREVENTION; URINARY TRACT HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; HEMORRHAGE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; RISK; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENTS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K;

EID: 84908124977     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.07.957     Document Type: Article

References (20)

1. S.V. Rao, K. O'Grady, and K.S. Pieper Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206
2. J.W. Eikelboom, S.R. Mehta, and S.S. Anand Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
3. P.G. Steg, K. Huber, and F. Andreotti Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 32 2011 1854 1864
4. T.D. Kinnaird, E. Stabile, and G.S. Mintz Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935
5. F.W. Verheugt, S.R. Steinhubl, and M. Hamon Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention J Am Coll Cardiol Intv 4 2011 191 197
6. J.P. Collet, G. Montalescot, and B. Blanchet Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes Circulation 110 2004 2361 2367
7. J. Silvain, A. Pena, and G. Cayla Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study Eur Heart J 31 2010 2816 2821
8. M.S. Sabatine, D.A. Morrow, and R.P. Giugliano Association of hemoglobin levels with clinical outcomes in acute coronary syndromes Circulation 111 2005 2042 2049
9. C. Bauters, M. Deneve, O. Tricot CORONOR Investigators Prognosis of patients with stable coronary artery disease (from the CORONOR Study) Am J Cardiol 113 2014 1142 1145
10. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
11. P.B. Berger, D.L. Bhatt, V. Fuster for the CHARISMA Investigators Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial Circulation 121 2010 2575 2583
12. G. Ducrocq, J.S. Wallace, G. Baron for the REACH Investigators Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis Eur Heart J 31 2010 1257 1265
13. M. Moscucci, K.A. Fox, and C.P. Cannon Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1815 1823
14. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery A.J. Camm, P. Kirchof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
15. J.P. DiMarco, G. Flaker, A.L. Waldo AFFIRM Investigators Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Am Heart J 149 2005 650 656
16. G.C. Flaker, M. Gruber, S.J. Connolly for the SPORTIF Investigators Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials Am Heart J 152 2006 967 973
17. G.Y. Lip Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation BMJ 336 2008 614 615
18. V. Fuster, L.E. Ryden, and D.S. Cannom 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 57 2011 e101 e198
19. G.Y. Lip, C. Laroche, and G.A. Dan 'Real-world' antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey Am J Med 127 2014 519 529.e1
20. W.J. Kikkert, N. van Geloven, and M.H. van der Laan The prognostic value of Bleeding Academic Research Consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications J Am Coll Cardiol 63 2014 1866 1875